| KOMISJA NADZORU FINANSOWEGO | ||||||||||||
| Raport bieżący nr | 14 | / | 2021 | |||||||||
| Data sporządzenia: | 2021-07-07 | |||||||||||
| Skrócona nazwa emitenta | ||||||||||||
| MILESTONE MEDICAL | ||||||||||||
| Temat | ||||||||||||
| Commencing Sales of CompuFlo® Instruments / CathCheck™ Verification System Disposables within the UTMB Health Clear Lake Campus Hospital | ||||||||||||
| Podstawa prawna | ||||||||||||
| Art. 17 ust. 1 MAR - informacje poufne. | ||||||||||||
| Treść raportu: | ||||||||||||
| The Board of Directors of Milestone Medical Inc. (WAR: MMD, “the Company", “the Issuer"), today announced that the University of Texas Medical Branch (UTMB) Health Clear Lake Campus Hospital has begun use of the CompuFlo Epidural Instrument. UTMB is an institution of the University of Texas System and agency of the State of Texas. UTMB is a major academic health sciences center of global influence, with medical, nursing, health professions and graduate biomedical schools; a world-renowned research enterprise; and a growing, comprehensive health system with hospitals on four campuses. As previously announced, the Company had begun selling CompuFlo disposables to the UTMB Health Galveston Campus Hospital. The Board of Directors of the Company is very pleased to announce that UTMB Health has expanded its use of the CompuFlo Epidural Instrument, including its consumables to its Clear Lake Campus Hospital. The agreement represents second hospital within the UTMB Health network. This expansion follows successful use of the instrument and disposables at the Galveston Campus Hospital and is strong validation of the favorable response to Milestone Scientific’s technology by leading anesthesiologists. The Board of Directors of the Company believes that the new sales force initiatives are taking hold, and interest in the technology is growing. | ||||||||||||
| MESSAGE (ENGLISH VERSION) | |||
| MILESTONE MEDICAL INC | ||||||||||||||||
| (pełna nazwa emitenta) | ||||||||||||||||
| MILESTONE MEDICAL | ||||||||||||||||
| (skrócona nazwa emitenta) | (sektor wg. klasyfikacji GPW w W-wie) | |||||||||||||||
| NJ 07039 | . | |||||||||||||||
| (kod pocztowy) | (miejscowość) | |||||||||||||||
| South Orange Avenue Livingston | 220 | |||||||||||||||
| (ulica) | (numer) | |||||||||||||||
| +11 973 535 2717 | +11 973 535 2829 | |||||||||||||||
| (telefon) | (fax) | |||||||||||||||
| (e-mail) | (www) | |||||||||||||||
| 27-5484393 | ||||||||||||||||
| (NIP) | (REGON) | |||||||||||||||
| PODPISY OSÓB REPREZENTUJĄCYCH SPÓŁKĘ | |||||
| Data | Imię i Nazwisko | Stanowisko/Funkcja | Podpis | ||
| 2021-07-07 | Arjan Haverhals | Chief Executive Officer | Arjan Haverhals | ||
